Concepedia

Erin Bliven-Sizemore

EB

10

Publications

1.5K

Citations

10

H-Index

2010

Active since

Affiliations

Centers for Disease Control and Prevention(Current)

The University of Texas Health Science Center at San Antonio

Johns Hopkins University

Johns Hopkins Medicine

University of California, San Francisco

Erin Bliven-Sizemore is an author at Centers for Disease Control and Prevention specializing in medicine, pharmacology, and drug discovery.

Top concepts

Publications per year

2010–2021

10

Publications

10

Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection

Timothy R. Sterling, Margarita E. Villarino, Andrey Borisov et al. · New England Journal of Medicine · 2011 · 946 citations · Full text

Effects of Tuberculosis, Race, and Human Gene <i>SLCO1B1</i> Polymorphisms on Rifampin Concentrations

Marc Weiner, Charles A. Peloquin, William J. Burman et al. · Antimicrobial Agents and Chemotherapy · 2010 · 154 citations · Full text

Safety and Pharmacokinetics of Escalating Daily Doses of the Antituberculosis Drug Rifapentine in Healthy Volunteers

Kelly E. Dooley, Erin Bliven-Sizemore, Marc Weiner et al. · Clinical Pharmacology & Therapeutics · 2012 · 89 citations · Full text

Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI

Erin Bliven-Sizemore, Timothy R. Sterling, N. Shang et al. · The International Journal of Tuberculosis and Lung Disease · 2015 · 70 citations · Full text

Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis

Payam Nahid, Erin Bliven-Sizemore, Leah G. Jarlsberg et al. · Tuberculosis · 2014 · 60 citations · Full text

, , +7

Rows per page

1–5 of 10